PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES

Marek Glezerman; Vered Cohen; Moshe Movshovitz; Jacob Shoham; Eitan Lunenfeld; Israel Sarov; Thomas Doerner; Michel Revel

doi:10.1016/S0140-6736(88)92723-7

PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES

Marek Glezerman, Vered Cohen, Moshe Movshovitz, Jacob Shoham, Eitan Lunenfeld, Israel Sarov, Thomas Doerner, Michel Revel

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

The efficacy of topical interferon-β (IFN-β) treatment was assessed in 25 patients with herpes of the lips or genitals who completed a 2-year follow-up in a double-blind placebo-controlled trial. IFN-β gel (10⁵ U/g) 4 times daily (about 2 × 10⁴ U) applied locally during eruptions (about 10 days) reduced the mean number of recurrences (p<0·007) and the duration of eruptions (p <0·007): in the placebo group these indices did not change significantly. Reduction of symptoms and severity was noted in 11 of 12 patients on IFN-β and in only 1 on placebo. No important side-effects were recorded. Topical IFN-β may therefore be advantageous as a time-limited local treatment of recurrent herpes simplex virus infections of the genitals and lips.

Original language	English
Pages (from-to)	150-152
Number of pages	3
Journal	The Lancet
Volume	331
Issue number	8578
DOIs	https://doi.org/10.1016/S0140-6736(88)92723-7
State	Published - 23 Jan 1988

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(88)92723-7

Cite this

@article{948a751ace8c47f8810395263544556b,

title = "PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES",

abstract = "The efficacy of topical interferon-β (IFN-β) treatment was assessed in 25 patients with herpes of the lips or genitals who completed a 2-year follow-up in a double-blind placebo-controlled trial. IFN-β gel (105 U/g) 4 times daily (about 2 × 104 U) applied locally during eruptions (about 10 days) reduced the mean number of recurrences (p<0·007) and the duration of eruptions (p <0·007): in the placebo group these indices did not change significantly. Reduction of symptoms and severity was noted in 11 of 12 patients on IFN-β and in only 1 on placebo. No important side-effects were recorded. Topical IFN-β may therefore be advantageous as a time-limited local treatment of recurrent herpes simplex virus infections of the genitals and lips.",

author = "Marek Glezerman and Vered Cohen and Moshe Movshovitz and Jacob Shoham and Eitan Lunenfeld and Israel Sarov and Thomas Doerner and Michel Revel",

year = "1988",

month = jan,

day = "23",

doi = "10.1016/S0140-6736(88)92723-7",

language = "English",

volume = "331",

pages = "150--152",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8578",

}

TY - JOUR

T1 - PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES

AU - Glezerman, Marek

AU - Cohen, Vered

AU - Movshovitz, Moshe

AU - Shoham, Jacob

AU - Lunenfeld, Eitan

AU - Sarov, Israel

AU - Doerner, Thomas

AU - Revel, Michel

PY - 1988/1/23

Y1 - 1988/1/23

N2 - The efficacy of topical interferon-β (IFN-β) treatment was assessed in 25 patients with herpes of the lips or genitals who completed a 2-year follow-up in a double-blind placebo-controlled trial. IFN-β gel (105 U/g) 4 times daily (about 2 × 104 U) applied locally during eruptions (about 10 days) reduced the mean number of recurrences (p<0·007) and the duration of eruptions (p <0·007): in the placebo group these indices did not change significantly. Reduction of symptoms and severity was noted in 11 of 12 patients on IFN-β and in only 1 on placebo. No important side-effects were recorded. Topical IFN-β may therefore be advantageous as a time-limited local treatment of recurrent herpes simplex virus infections of the genitals and lips.

AB - The efficacy of topical interferon-β (IFN-β) treatment was assessed in 25 patients with herpes of the lips or genitals who completed a 2-year follow-up in a double-blind placebo-controlled trial. IFN-β gel (105 U/g) 4 times daily (about 2 × 104 U) applied locally during eruptions (about 10 days) reduced the mean number of recurrences (p<0·007) and the duration of eruptions (p <0·007): in the placebo group these indices did not change significantly. Reduction of symptoms and severity was noted in 11 of 12 patients on IFN-β and in only 1 on placebo. No important side-effects were recorded. Topical IFN-β may therefore be advantageous as a time-limited local treatment of recurrent herpes simplex virus infections of the genitals and lips.

UR - http://www.scopus.com/inward/record.url?scp=0023837879&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(88)92723-7

DO - 10.1016/S0140-6736(88)92723-7

M3 - Article

C2 - 2892991

AN - SCOPUS:0023837879

SN - 0140-6736

VL - 331

SP - 150

EP - 152

JO - The Lancet

JF - The Lancet

IS - 8578

ER -

PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this